CVS Health Co. (NYSE:CVS) Shares Sold by Securian Asset Management Inc.

Securian Asset Management Inc. cut its position in shares of CVS Health Co. (NYSE:CVS) by 2.6% during the 2nd quarter, Holdings Channel reports. The firm owned 72,184 shares of the pharmacy operator’s stock after selling 1,937 shares during the period. Securian Asset Management Inc.’s holdings in CVS Health were worth $4,263,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Wedmont Private Capital boosted its stake in shares of CVS Health by 0.8% during the 1st quarter. Wedmont Private Capital now owns 19,225 shares of the pharmacy operator’s stock worth $1,410,000 after acquiring an additional 146 shares in the last quarter. Bank of Stockton boosted its stake in shares of CVS Health by 4.5% during the 1st quarter. Bank of Stockton now owns 3,467 shares of the pharmacy operator’s stock worth $277,000 after acquiring an additional 150 shares in the last quarter. Moody National Bank Trust Division boosted its stake in shares of CVS Health by 0.7% during the 1st quarter. Moody National Bank Trust Division now owns 22,268 shares of the pharmacy operator’s stock worth $1,776,000 after acquiring an additional 150 shares in the last quarter. Landmark Financial Advisors LLC boosted its stake in shares of CVS Health by 3.8% during the 4th quarter. Landmark Financial Advisors LLC now owns 4,166 shares of the pharmacy operator’s stock worth $329,000 after acquiring an additional 153 shares in the last quarter. Finally, Sepio Capital LP boosted its stake in shares of CVS Health by 1.7% during the 4th quarter. Sepio Capital LP now owns 9,907 shares of the pharmacy operator’s stock worth $782,000 after acquiring an additional 163 shares in the last quarter. 80.66% of the stock is currently owned by institutional investors and hedge funds.

CVS Health Stock Performance

Shares of CVS Health stock traded down $1.17 during trading on Monday, reaching $55.94. The company’s stock had a trading volume of 4,450,623 shares, compared to its average volume of 11,500,823. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.61 and a current ratio of 0.81. The business’s fifty day moving average price is $59.45 and its 200-day moving average price is $66.14. The firm has a market cap of $70.23 billion, a price-to-earnings ratio of 9.92, a price-to-earnings-growth ratio of 0.57 and a beta of 0.52. CVS Health Co. has a one year low of $52.77 and a one year high of $83.25.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Wednesday, August 7th. The pharmacy operator reported $1.83 EPS for the quarter, topping analysts’ consensus estimates of $1.73 by $0.10. The business had revenue of $91.23 billion for the quarter, compared to analyst estimates of $91.41 billion. CVS Health had a return on equity of 13.53% and a net margin of 2.03%. The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same period in the previous year, the company posted $2.21 earnings per share. As a group, equities research analysts predict that CVS Health Co. will post 7 earnings per share for the current year.

CVS Health Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, August 1st. Investors of record on Monday, July 22nd were paid a dividend of $0.665 per share. The ex-dividend date was Monday, July 22nd. This represents a $2.66 annualized dividend and a yield of 4.76%. CVS Health’s dividend payout ratio is 46.75%.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on CVS shares. Evercore ISI reduced their price objective on CVS Health from $65.00 to $62.00 and set an “outperform” rating for the company in a research note on Thursday. The Goldman Sachs Group decreased their target price on CVS Health from $85.00 to $74.00 and set a “buy” rating for the company in a research report on Thursday, May 2nd. Cantor Fitzgerald raised their target price on CVS Health from $58.00 to $62.00 and gave the stock a “neutral” rating in a research report on Thursday. Robert W. Baird assumed coverage on CVS Health in a research report on Thursday, May 30th. They issued a “neutral” rating and a $61.00 target price for the company. Finally, Mizuho decreased their target price on CVS Health from $86.00 to $72.00 and set a “buy” rating for the company in a research report on Thursday, May 2nd. Twelve analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $73.24.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.